Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 18/20 | 0.75 |
| ▸ | BRD4 | O60885 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | BRD2 | P25440 | 1/20 | 0.52 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.52 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL4905677 | 0.95 | CSF1R (0.68) | CSF1RBRD4CYP3A4CYP2C9BRD2 | |
| SCHEMBL4915644 | 0.91 | CSF1R (0.67) | CSF1RNUDT1 | |
| SCHEMBL4907869 | 0.89 | CSF1R (0.64) | CSF1RNUDT1 | |
| SCHEMBL4915128 | 0.88 | CSF1R (0.63) | CSF1R | |
| SCHEMBL4909912 | 0.88 | CSF1R (0.63) | CSF1R | |
| SCHEMBL5929706 | 0.87 | CSF1R (1.00) | CSF1RNUDT1 | |
| Trifluoroacetic Acid SCHEMBL4913946 | 0.84 | CSF1R (0.61) | CSF1RNUDT1 | |
| SCHEMBL5929680 | 0.84 | CSF1R (0.80) | CSF1RNUDT1 | |
| Trifluoroacetic Acid SCHEMBL4912742 | 0.84 | CSF1R (0.61) | CSF1RNUDT1 | |
| Trifluoroacetic Acid SCHEMBL4915084 | 0.84 | CSF1R (0.61) | CSF1RNUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080153799-A1 | Novel Quinoline-Carbaxamides as Jak3 Kinase Modulators | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | US | claimed |
| EP-1718615-A1 | NOVEL QUINOLINE-CARBAXAMIDES AS JACK3 KINASE MODULATORS | AstraZeneca AB (SE) | 2006-11-08 | — | — | EP | claimed |
| WO-2005075429-A1 | NOVEL QUINOLINE-CARBAXAMIDES AS JACK3 KINASE MODULATORS | ASTRAZENECA AB (SE) | 2005-08-18 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153799-A1 | Novel Quinoline-Carbaxamides as Jak3 Kinase Modulators | JAK3, JAK1, JAK2 | CSF1R 626/4885BRD4 71/4885CYP3A4 1995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.